Anlon Healthcare Q2 FY27 Revenue Up 102% YoY

Event Type: Q2/H1 FY27 Earnings Conference Call hosted by X-B4 Advisory, including a question-and-answer session with management.

Date and Time: The conference call was held on November 03, 2026. The specific time was not mentioned in the disclosure.

Purpose: Discussion of quarterly results, strategic progress, and operational updates for Q2 and H1 FY27.

Management Participants: Mr. Punitkumar Rasadia, Chairman and Managing Director of Anlon Healthcare Limited, represented management. The moderator was Mr. Divya Shethia from X-B4 Advisory.

Presentation Availability: The company confirmed that an investor presentation had been uploaded on the stock exchange and company's website (www.anlon.in). The transcript of the earnings call was being made available as part of this regulatory filing.

UPSI Statement: The disclosure included a standard safe harbor statement indicating that the conference call may contain forward-looking statements that are not guarantees of future performance and may involve risks and uncertainties.

Financial Period Discussed: Q2 FY27 (Quarter ended September 2026) and H1 FY27 (Half year ended September 2026) results were discussed in detail.

Forward-Looking Statements: Management provided revenue guidance of INR380-400 crores for FY27 and INR650-700 crores for FY28. They also discussed expectations for EBITDA margins stabilizing in the 25-30% range, with current Q2 FY27 margin at 23.9%.

Q2 FY27 Performance (Consolidated):

Revenue from operations: INR105.61 crores (vs. INR52.2 crores in Q2 FY26, +102.3%)
EBITDA: INR25.24 crores (vs. INR13.71 crores in Q2 FY26, +84.1%)
Profit after tax: INR17.18 crores (vs. INR9.32 crores in Q2 FY26, +84.4%)

H1 FY27 Performance (Consolidated):

Revenue from operations: INR193.17 crores (vs. INR85.5 crores in H1 FY26, +125.9%)
EBITDA: INR40.83 crores (vs. INR19.95 crores in H1 FY26, +104.7%)
EBITDA margin: 21.1%
Profit after tax: INR25.46 crores (vs. INR12.86 crores in H1 FY26, +97.9%)

Operational Highlights:

H1 FY27 revenue exceeded full FY26 revenue
Net cash used in operating activities in H1 FY27 was INR7.94 crores (vs. INR79.44 crores for full FY26)
Working capital cycle improvement with receivables reduced to 90-100 days from 130-140 days
Current installed manufacturing capacity: 1,900-2,000 MTPA across the group
Greenfield expansion at Rajkot will add 1,200 MTPA through 8 new clean lines (commissioning Q1 FY28)
Additional 500 MTPA expansion planned across the group
21 DMFs filed with global authorities, with 5-7 expected to commercialize during FY27
Targeting 3-5 additional DMF filings in FY27
Ketoprofen DMF filing for U.S. market underway

Business Segment Contributions (H1 FY27):

Anlon Stand-alone Product Mix:

CDMO Business Update:

Developing 3 molecules for 2 global innovator companies
Validation quantities for first molecule supplied, commercial supplies targeted from Q3 FY27
Remaining 2 molecules in validation, commercialization targeted between Q4 FY27 to Q1 FY28

Subsidiary Updates:

Anlon Medicos (finished dosage formulations): Expected first revenue in Q4 FY27
Anlon Biologics (peptides, oligonucleotides, biosimilars): Expected first revenue in Q4 FY28
Anlon Medico (surgical implants and medical devices): Structured separately

Regulatory Status:

DMF approvals from PMDA Japan, NMPA China, and ANVISA Brazil for Loxoprofen
CEP from EDQM Europe for Ketoprofen
Loxoprofen topical gel regulatory filings underway with CDSCO and DCGI, approval anticipated in FY28

The document includes the complete transcript of the earnings conference call held on November 03, 2026.

The filing was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No financial data beyond what was presented in the conference call transcript was disclosed in this announcement.

The document was digitally signed by Mr. Punitkumar Rasadia, Managing Director (DIN: 06696258).